Benjamin Auberger (@Benny8680) header
Benjamin Auberger (@Benny8680) profile picture

Medical Oncologist, Urologic #Oncology #GUcancer. Running Addict.🏃🏻🏃🏻@CHRU_Brest.Views are mine

Brest, France
Joined May 2012
Photo by Benjamin Auberger (@Benny8680)Photo by Benjamin Auberger (@Benny8680)Photo by Benjamin Auberger (@Benny8680)Photo by Benjamin Auberger (@Benny8680)Photo by Benjamin Auberger (@Benny8680)Photo by Benjamin Auberger (@Benny8680)Photo by Benjamin Auberger (@Benny8680)Photo by Benjamin Auberger (@Benny8680)Photo by Benjamin Auberger (@Benny8680)Photo by Benjamin Auberger (@Benny8680)
Benjamin Auberger retweeted
Trials are critical for defining what comes after EV + pembrolizumab (EV/P) in advanced bladder cancer? 🧵 1/9 At @MSKCancerCenter with @MSK_DeptOfMed @UrologyMSK we're exploring all these approaches through several clinical trials to overcome EV resistance New Patients Contact for appointments: 866-432-3416 mskcc.org/experience/become-… - NEW cancer targets (TROP2, EGFR/HER3) - NEW ADC payloads (Topo-I) - T-cell engagers - Radioligand therapies @MSK_DeptOfMed #blcsm
1
18
38
4,001
Benjamin Auberger retweeted
Decades of progress. Thousands of courageous patients, families, and researchers. Progress is never just about drugs. It is about people. And our work is far from over. What comes next? @OncoAlert @OpenMedicineHQ @APCCC_Lugano #prostatecancer
🤖 Made with AI
4
46
2
102
7,072
Benjamin Auberger retweeted
What’s next for front-line metastatic RCC? #UromigosLive #UroVoices
1
1
178
Benjamin Auberger retweeted
Replying to @brian_rini
@brian_rini is still the best at making tables Good discussion of the correct patient for ARPI treatment intensification for locally advanced or N+ prostate cancer #UromigosLive #uromigos
🤖 Made with AI
1
18
30
2,200
Benjamin Auberger retweeted
Did proteus enroll too high risk or not high risk enough a patient population? “It’s not the right risk group if the goal is MFS or OS” “It is the right group if the endpoint is time to next treatment” @AttardLab #UromigosLive #uromigos @OncoAlert
9
13
1,012
Benjamin Auberger retweeted
Summary of ctDNA across studied #UromigosLIVE #UroVOICES @OncoAlert
16
25
1,337
Benjamin Auberger retweeted
Here are the phase III trials on-going for front-line mUC. Second time @tompowles1 used win on the swings and lose on the roundabouts. Team 🇺🇸 needed help with that reference #Uromigoslive #UroVOICES #Oncoalert @OncoAlert
10
10
811
Benjamin Auberger retweeted
Healthy discussion on the success of EV based perioperative therapy - every patient with MIBC should have a consult with medical oncology to discuss risks and benefits of therapy #uroVOICES #uromigoslive @Uromigos
12
14
1,111
Benjamin Auberger retweeted
Persistent ctDNA positivity post EV/PD(L)1 pre cystectomy is a negative prognostic factor #UromigosLIVE #UroVoices
5
8
322
Benjamin Auberger retweeted
On to discuss bladder sparing - TroFuse55 is the only trial addressing if a benefit to chemoRT after ADC + I/O therapy #UromigosLIVE #UROVOICES @OncoAlert
13
1
18
1,543
Benjamin Auberger retweeted
🎯 Precision oncology means identifying the right patients—not just the right drugs! Excellent overview of the striking heterogeneity in PARP inhibitor benefit across HRR alterations in mCRPC. 🧬 BRCA2 remains the strongest predictor of benefit, while ATM and CHEK2 alterations show much less convincing responses. HRR-mutated ≠ HRD ≠ PARPi-sensitive! Gene-level biology matters. We need to move beyond binary HRR-positive labels toward functional biomarkers of homologous recombination deficiency. Great summary! 👏 @dmukherji @zklaassen_md @urotoday @OncoAlert @weoncologists @urotoday @Uromigos @OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3
#ESMO26 Management of mCRPC: Personalized treatment selection and sequencing @dmukherji @urotoday Spectrum of PARPi sensitivity in mCRPC by HRR gene alteration Evidence from PROfound, MAGNITUDE, TALAPRO-2, PROpel, and FDA pooled analysis
1
15
42
2,631
Benjamin Auberger retweeted
At #ESMO26 we introduced a new word, #RIPTAC, JNJ-6143. Introducing another innovation presented @sitcancer yesterday! FIH Investigational combo of Pasritamig our @JNJInnovMed KLK2xCD3 T-cell agent + our PSMA x CD28 co-stim JNJ-9401. Signal 1 & signal 2 together! #MyCompany
6
27
1
80
8,266
Benjamin Auberger retweeted
#EMUC26 Risk of MACE with Daro vs Enza in Advanced PCa: RW 🇺🇸 Observational Study @hannahdzmd @urotoday Daro (n=1737) vs Enza (n=4373): 📍All PCa Pts: - 3 Pt MACE: MV model (HR 0.81, 95%CI 0.69-0.95); IPTW (HR 0.82, 95%CI 0.69-0.96) - 4 Pt MACE: MV model (HR 0.85, 95%CI 0.73-0.98); IPTW (HR 0.84, 95%CI 0.72-0.97) - 24 mo probability of 3 Pt MACE (16.1% vs 18.4%) or 4 Pt MACE (19.5% vs 21.2%) 📍mHSPC Pts: - 3 Pt MACE: MV model (HR 0.73, 95%CI 0.59-0.91); IPTW (HR 0.72, 95%CI 0.58-0.90) - 4 Pt MACE: MV model (HR 0.80, 95%CI 0.66-0.98); IPTW (HR 0.80, 95%CI 0.66-0.98) - 24 mo probability of 3 Pt MACE (14.3% vs 19.9%) or 4 Pt MACE (18.2% vs 22.3%)
13
19
2,096
Benjamin Auberger retweeted
#PEACE3 at #EMUC26: a lasting survival benefit. At 4 years, 39.4% alive with enzalutamide + radium-223 vs 29.0% with enzalutamide alone in mCRPC. +10.4 percentage points in overall survival. Bone protection is essential. #ProstateCancer @EORTC @LACOG_group @GETUG_Unicancer @cancertrials_ie #CUOG @RayMcDermott1 @Silke_Gillessen
27
1
65
2,776
Benjamin Auberger retweeted
We touched on 5 🔑 studies during our GU Malignancies Highlights from #ESMO26 w/ @shilpaonc & @UroDocAsh ⭐️ #VOLGA ⭐ #DASLHICaP & #PROTEUS ⭐ #KEYNOTE564 ⭐ #LITESPARK022 #OncTwitter #gusm @OncUpdates @myESMO
GU Malignancies Conference Highlights from #ESMO26 w/ @shilpaonc & @UroDocAsh ✅ #VOLGA ✅ #DASL-HiCaP (#PROTEUS) ✅ #KEYNOTE564 ✅ #LITESPARK011 Full 🗣️ ⭐️ oncbrothers.com/esmogu26 ⭐️“Oncology Brothers” podcast #OncTwitter #gusm #MedTwitter #BladderCancer
1
34
2
72
8,849
Benjamin Auberger retweeted
Talazoparib now @FDA ✅ based off TALAPRO-3: Enzalutamide + Talazoparib vs. Enza alone in HRR mutated mCSPC: - At 3yrs, rPFS: 76.6% vs. 56.2% (HR: 0.48) - rPFS in BRCAm: 77.2% vs. 48.8% (HR: 0.37) - rPFS in nonBRCA: 76.2% vs. 60.2% (HR: 0.57) #OncTwitter #gusm #ProstateCancer
1
18
1
33
3,325
Benjamin Auberger retweeted
#ESMO26 Upcoming Bladder Preservation Trials -- Laura Mertens Key phase II and III studies for our patients @urotoday
3
28
59
3,537
Benjamin Auberger retweeted
#ESMO26 Can we personalize and de-escalate treatment strategies in MIBC? @urotoday Two 🔑 checklists from @giannatempopatr 1) Personalizing peri-operative treatment today 2) De-escalation strategies in MIBC today
9
19
1,061
Benjamin Auberger retweeted
Bladder preservation after neoadjuvant/perioperative therapy in 🇮🇹 MIBC pts who declined RC and underwent reTURBT (n=54) 📌Negative imaging, biopsy & cytology 🔹19% recurred; 13% developed distant recurrence 🔹 ypT0Nx at reTURBT → 24-mo EFS 88%; MFS & OS >95%, comparable with ypT0N0 after RC 🔹 Residual disease at reTURBT → substantially worse vs non-pCR after RC: 24-mo EFS 19% vs 68%; OS 50% vs 83% 🔹 20% required delayed RC or chemoRT 🔹 Baseline cT3–4 disease also associated with poorer outcomes 🔑 Pathologic clearance at reTURBT may identify a highly selected group for bladder preservation; residual disease was associated with markedly inferior outcomes vs RC. @urotoday #ESMO26
22
2
48
5,537
Envie de pleurer..
🔥 Emeutes et incendie de l'hôtel de Ville à Limoges : le clocher s'est écroulé ce soir, l'édifice historique semble complètement perdu.
83